Association between adiposity and cardiovascular outcomes: an umbrella review and meta-analysis of observational and Mendelian randomization studies

Min Seo Kim, Won Jun Kim, Amit V Khera, Jong Yeob Kim, Dong Keon Yon, Seung Won Lee, Jae Il Shin, Hong-Hee Won, Min Seo Kim, Won Jun Kim, Amit V Khera, Jong Yeob Kim, Dong Keon Yon, Seung Won Lee, Jae Il Shin, Hong-Hee Won

Abstract

Aims: The aim of this study was to investigate the causal relationship and evidence of an association between increased adiposity and the risk of incident cardiovascular disease (CVD) events or mortality.

Methods and results: Observational (informing association) and Mendelian randomization (MR) (informing causality) studies were assessed to gather mutually complementary insights and elucidate perplexing epidemiological relationships. Systematic reviews and meta-analyses of observational and MR studies that were published until January 2021 and evaluated the association between obesity-related indices and CVD risk were searched. Twelve systematic reviews with 53 meta-analyses results (including over 501 cohort studies) and 12 MR studies were included in the analysis. A body mass index (BMI) increase was associated with higher risks of coronary heart disease, heart failure, atrial fibrillation, all-cause stroke, haemorrhagic stroke, ischaemic stroke, hypertension, aortic valve stenosis, pulmonary embolism, and venous thrombo-embolism. The MR study results demonstrated a causal effect of obesity on all indices but stroke. The CVD risk increase for every 5 kg/m2 increase in BMI varied from 10% [relative risk (RR) 1.10; 95% confidence interval (CI) 1.01-1.21; certainty of evidence, low] for haemorrhagic stroke to 49% (RR 1.49; 95% CI 1.40-1.60; certainty of evidence, high) for hypertension. The all-cause and CVD-specific mortality risks increased with adiposity in cohorts, but the MR studies demonstrated no causal effect of adiposity on all-cause mortality.

Conclusion: High adiposity is associated with increased CVD risk despite divergent evidence gradients. Adiposity was a causal risk factor for CVD except all-cause mortality and stroke. Half (49%; 26/53) of the associations were supported by high-level evidence. The associations were consistent between sexes and across global regions. This study provides guidance on how to integrate evidence from observational (association) and genetics-driven (causation) studies accumulated to date, to enable a more reliable interpretation of epidemiological relationships.

Keywords: Cardiovascular disease; Coronary heart disease; Mendelian randomization study; Meta-analysis; Stroke; Umbrella review.

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

Figures

https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8423481/bin/ehab454f6.jpg
Observational studies (informing associations) and Mendelian randomization studies (informing causality) provided mutually complementary insight and enabled a more reliable interpretation of perplexing epidemiological relationships. This figure was constructed based on the summary of evidence shown in Table 1.
Figure 1
Figure 1
Flow diagram of the study search and selection process.
Figure 2
Figure 2
Collective results of observational studies. (A) Increased risk of cardiovascular events with elevated continuous and categorical body mass index. (B) Increased risk of death with elevated continuous body mass index. All results are based on random-effect models. The cohort and participant columns display the number of independent cohorts and the total number of participants incorporated in the meta-analysis for the outcome. The certainty of evidence underlying each association between body mass index and cardiovascular outcomes was evaluated using the GRADE framework. BMI, body mass index; ES, effect size; GRADE, Grading of Recommendations Assessment, Development, and Evaluation; HR, hazard ratio; OR, odds ratio; RR, risk ratio or relative risk.
Figure 3
Figure 3
Collective results of Mendelian randomization studies. (A) Increased risk of cardiovascular events per 1 kg/m2 increase in body mass index. (B) Increased risk of cardiovascular events per 5 kg/m2 increase in body mass index. (C) Increased risk of death per 1 kg/m2 increase in body mass index. All results are based on random-effects models. The cohort and cases columns display the number of independent cohorts and the number of cases incorporated in the meta-analysis for the outcome. BMI, body mass index; ES, effect size; HR, hazard ratio; OR, odds ratio; RR, risk ratio or relative risk.
Figure 4
Figure 4
Subgroup analyses of risk of cardiovascular diseases for central adiposity (A), categorical body mass index (B), and sex (C). All results are based on random-effects models. The cohort and participant columns display the number of independent cohorts and the total number of participants incorporated in the meta-analysis for the outcome. The certainty of evidence was evaluated using the GRADE framework. BMI, body mass index; GRADE, Grading of Recommendations Assessment, Development, and Evaluation; RR, risk ratio or relative risk.
Figure 5
Figure 5
Risks of cardiovascular incidences and mortalities were re-analysed according to regions. BMI, body mass index; CVD, cardiovascular disease; CHD, coronary heart disease; ES, effect size; HR, hazard ratio; OR, odds ratio; RR, risk ratio or relative risk.

References

    1. GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med 2017;377:13–27.
    1. Wang G, Zheng Z-J, Heath G, Macera C, Pratt M, Buchner D.. Economic burden of cardiovascular disease associated with excess body weight in US adults. Am J Prev Med 2002;23:1–6.
    1. Cappuccio FP, Miller MA.. Cardiovascular disease and hypertension in sub-Saharan Africa: burden, risk and interventions. Intern Emerg Med 2016;11:299–305.
    1. Emamgholipour S, Sari AA, Pakdaman M, Geravandi S.. Economic burden of cardiovascular disease in the southwest of Iran. Int Cardiovasc Res J 2018;12:6–12.
    1. Gaziano TA.Economic burden and the cost-effectiveness of treatment of cardiovascular diseases in Africa. Heart 2008;94:140–144.
    1. Luengo-Fernandez R, Leal J, Gray A, Petersen S, Rayner M.. Cost of cardiovascular diseases in the United Kingdom. Heart 2006;92:1384–1389.
    1. Anand SS, Yusuf S.. Stemming the global tsunami of cardiovascular disease. Lancet 2011;377:529–532.
    1. TikkanenE, , GustafssonS, , KnowlesJW, , PerezM, , BurgessS, , Ingelsson E.. Body composition and atrial fibrillation: a Mendelian randomization study. Eur Heart J2019;40:1277–1282.
    1. LauridsenBK, , StenderS, , KristensenTS, , KofoedKF, , KøberL, , NordestgaardBG, , Tybjærg-Hansen A.. Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals. Eur Heart J2018;39:385–393.
    1. Romero-CorralA, , SomersVK, , Sierra-JohnsonJ, , KorenfeldY, , BoarinS, , KorinekJ, , JensenMD, , ParatiG, , Lopez-Jimenez F.. Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality. Eur Heart J2010;31:737–746.
    1. ChenG-C, , ArthurR, , IyengarNM, , KamenskyV, , XueX, , Wassertheil-SmollerS, , AllisonMA, , ShadyabAH, , WildRA, , SunY, , BanackHR, , ChaiJC, , Wactawski-WendeJ, , MansonJE, , StefanickML, , DannenbergAJ, , RohanTE, , Qi Q.. Association between regional body fat and cardiovascular disease risk among postmenopausal women with normal body mass index. Eur Heart J2019;40:2849–2855.
    1. IliodromitiS, , Celis-MoralesCA, , LyallDM, , AndersonJ, , GraySR, , MackayDF, , NelsonSM, , WelshP, , PellJP, , GillJMR, , Sattar N.. The impact of confounding on the associations of different adiposity measures with the incidence of cardiovascular disease: a cohort study of 296 535 adults of white European descent. Eur Heart J 2018;39:1514–1520.
    1. Papatheodorou S.Umbrella reviews: what they are and why we need them. Eur J Epidemiol 2019;34:543–546.
    1. Biondi-Zoccai G.Umbrella reviews. In: Evidence Synthesis with Overviews of Reviews and Meta-Epidemiologic Studies. Cham, Switzerland: Springer International; 2016;3–391.
    1. Fusar-Poli P, Radua J.. Ten simple rules for conducting umbrella reviews. Evid Based Ment Health 2018;21:95–100.
    1. Aromataris E, Fernandez R, Godfrey CM, Holly C, Khalil H, Tungpunkom P.. Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach. JBI Evidence Implement 2015;13:132–140.
    1. Pingault J-B, O'Reilly PF, Schoeler T, Ploubidis GB, Rijsdijk F, Dudbridge F.. Using genetic data to strengthen causal inference in observational research. Nat Rev Genet 2018;19:566–580.
    1. Li X, Meng X, Timofeeva M, Tzoulaki I, Tsilidis KK, Ioannidis JP, Campbell H, Theodoratou E.. Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies. BMJ 2017;357:j2376.
    1. Köhler CA, Evangelou E, Stubbs B, Solmi M, Veronese N, Belbasis L, Bortolato B, Melo MCA, Coelho CA, Fernandes BS, Olfson M, Ioannidis JPA, Carvalho AF.. Mapping risk factors for depression across the lifespan: an umbrella review of evidence from meta-analyses and Mendelian randomization studies. J Psychiatr Res 2018;103:189–207.
    1. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010;8:336–341.
    1. Davies NM, Holmes MV, Smith GD.. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ 2018;362:k601.
    1. Emdin CA, Khera AV, Kathiresan S.. Mendelian randomization. JAMA 2017;318:1925–1926.
    1. Higgins J, Thompson SG.. Quantifying heterogeneity in a meta‐analysis. Stat Med 2002;21:1539–1558.
    1. Egger M, Smith GD.. Bias in location and selection of studies. BMJ 1998;316:61–66.
    1. van Aert RCM, Wicherts JM, van Assen M.. Publication bias examined in meta-analyses from psychology and medicine: a meta-meta-analysis. PLoS One 2019;14:e0215052.
    1. van Assen MA, van Aert RC, Wicherts JM.. Meta-analysis using effect size distributions of only statistically significant studies. Psychol Methods 2015;20:293–309.
    1. Mertens G, Engelhard IM.. A systematic review and meta-analysis of the evidence for unaware fear conditioning. Neurosci Biobehav Rev 2020;108:254–268.
    1. Simonsohn U, Nelson LD, Simmons JP.. p-Curve and effect size: correcting for publication bias using only significant results. Perspect Psychol Sci 2014;9:666–681.
    1. Higgins JP.Commentary: heterogeneity in meta-analysis should be expected and appropriately quantified. Int J Epidemiol 2008;37:1158–1160.
    1. Riley RD, Higgins JP, Deeks JJ.. Interpretation of random effects meta-analyses. BMJ 2011;342:d549.
    1. IntHout J, Ioannidis JP, Rovers MM, Goeman JJ.. Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open 2016;6:e010247.
    1. Xu C, Niu Y, Wu J, Gu H, Zhang C.. Software and package applicating for network meta-analysis: a usage-based comparative study. J Evid Based Med 2018;11:176–183.
    1. IntHout J, Ioannidis JP, Borm GF.. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol 2014;14:1–12.
    1. Sidik K, Jonkman JN.. Simple heterogeneity variance estimation for meta‐analysis. J R Stat Soc Ser C (Appl Stat) 2005;54:367–384.
    1. Kim A, Kim MS, Park YJ, Choi WS, Park HK, Paick SH, Choo MS, Kim HG.. Clinical outcome of single-incision slings, excluding TVT-Secur, vs standard slings in the surgical management of stress incontinence: an updated systematic review and meta-analysis. BJU Int 2019;123:566–584.
    1. Kim A, Kim MS, Park YJ, Choi WS, Park HK, Paick SH, Kim HG.. Retropubic versus transobturator mid urethral slings in patients at high risk for recurrent stress incontinence: a systematic review and meta-analysis. J Urol 2019;202:132–142.
    1. Kim MS, An MH, Kim WJ, Hwang TH.. Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: a systematic review and network meta-analysis. PLoS Med 2020;17:e1003501.
    1. Puhan MA, Schünemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, Kessels AG, Guyatt GH; GRADE Working Group. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 2014;349:g5630.
    1. Shekelle PG, Maglione MA, Luoto J, Johnsen B, Perry TR.. AHRQ methods for effective health care. In:Global Health Evidence Evaluation Framework. Rockville, MD: Agency for Healthcare Research and Quality (US; ) 2013;3–24.
    1. Ho PM, Peterson PN, Masoudi FA.. Evaluating the evidence: is there a rigid hierarchy? Circulation 2008;118:1675–1684.
    1. Katz DL, Karlsen MC, Chung M, Shams-White MM, Green LW, Fielding J, Saito A, Willett W.. Hierarchies of evidence applied to lifestyle Medicine (HEALM): introduction of a strength-of-evidence approach based on a methodological systematic review. BMC Med Res Methodol 2019;19:178.
    1. Zhang Y, Coello PA, Guyatt GH, Yepes-Nuñez JJ, Akl EA, Hazlewood G, Pardo-Hernandez H, Etxeandia-Ikobaltzeta I, Qaseem A, Williams JW, Tugwell P, Flottorp S, Chang Y, Zhang Y, Mustafa RA, Rojas MX, Xie F, Schünemann HJ.. GRADE guidelines: 20. Assessing the certainty of evidence in the importance of outcomes or values and preferences–inconsistency, imprecision, and other domains. J Clin Epidemiol 2019;111:83–93.
    1. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G.. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med 2008;27:1133–1163.
    1. Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute 2011. p1–12.
    1. Iorio A, Spencer FA, Falavigna M, Alba C, Lang E, Burnand B, McGinn T, Hayden J, Williams K, Shea B, Wolff R, Kujpers T, Perel P, Vandvik PO, Glasziou P, Schunemann H, Guyatt G.. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. BMJ 2015;350:h870.
    1. Aune D, Sen A, Prasad M, Norat T, Janszky I, Tonstad S, Romundstad P, Vatten LJ.. BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants. BMJ 2016;353:i2156.
    1. Wade KH, Carslake D, Sattar N, Davey Smith G, Timpson NJ.. BMI and mortality in UK Biobank: revised estimates using Mendelian randomization. Obesity 2018;26:1796–1806.
    1. Haycock PC, Burgess S, Wade KH, Bowden J, Relton C, Davey Smith G.. Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies. Am J Clin Nutr 2016;103:965–978.
    1. Pierce BL, Burgess S.. Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. Am J Epidemiol 2013;178:1177–1184.
    1. Burgess S, Thompson SG.. Bias in causal estimates from Mendelian randomization studies with weak instruments. Stat Med 2011;30:1312–1323.
    1. Khera AV, Chaffin M, Wade KH, Zahid S, Brancale J, Xia R, Distefano M, Senol-Cosar O, Haas ME, Bick A, Aragam KG, Lander ES, Smith GD, Mason-Suares H, Fornage M, Lebo M, Timpson NJ, Kaplan LM, Kathiresan S.. Polygenic prediction of weight and obesity trajectories from birth to adulthood. Cell 2019;177:587–596.e9.
    1. Smith GD, Ebrahim S.. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol 2004;33:30–42.
    1. Van Gaal LF, Mertens IL, Christophe E.. Mechanisms linking obesity with cardiovascular disease. Nature 2006;444:875–880.
    1. Cachofeiro V, Miana M, Heras N, Martín-Fernandez B, Ballesteros S, Balfagon G, Lahera V.. Inflammation: a link between hypertension and atherosclerosis. Curr Hypertens Rev 2009;5:40–48.
    1. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC, Virani SS, Williams KA, Yeboah J, Ziaeian B.. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019;74:e177–e232.
    1. Schulz E, Gori T, Münzel T.. Oxidative stress and endothelial dysfunction in hypertension. Hypertens Res 2011;34:665–673.
    1. Palla M, Saber H, Konda S, Briasoulis A.. Masked hypertension and cardiovascular outcomes: an updated systematic review and meta-analysis. Integr Blood Press Control 2018;11:11–24.
    1. Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA.. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA 2011;305:913–922.
    1. Li W, Zhao J, Song L, Chen S, Liu X, Wu S.. Combined effects of carotid plaques and hypertension on the risk of cardiovascular disease and all-cause mortality. Clin Cardiol 2020;43:715–722.
    1. Rodriguez CJ, Swett K, Agarwal SK, Folsom AR, Fox ER, Loehr LR, Ni H, Rosamond WD, Chang PP.. Systolic blood pressure levels among adults with hypertension and incident cardiovascular events: the atherosclerosis risk in communities study. JAMA Intern Med 2014;174:1252–1261.
    1. Holmes MV, Lange LA, Palmer T, Lanktree MB, North KE, Almoguera B, Buxbaum S, Chandrupatla HR, Elbers CC, Guo Y, Hoogeveen RC, Li J, Li YR, Swerdlow DI, Cushman M, Price TS, Curtis SP, Fornage M, Hakonarson H, Patel SR, Redline S, Siscovick DS, Tsai MY, Wilson JG, van der Schouw YT, FitzGerald GA, Hingorani AD, Casas JP, de Bakker PIW, Rich SS, Schadt EE, Asselbergs FW, Reiner AP, Keating BJ.. Causal effects of body mass index on cardiometabolic traits and events: a Mendelian randomization analysis. Am J Hum Genet 2014;94:198–208.
    1. Lyall DM, Celis-Morales C, Ward J, Iliodromiti S, Anderson JJ, Gill JMR, Smith DJ, Ntuk UE, Mackay DF, Holmes MV, Sattar N, Pell JP.. Association of body mass index with cardiometabolic disease in the UK Biobank: a Mendelian randomization study. JAMA Cardiol 2017;2:882–889.
    1. Fall T, Hägg S, Mägi R, Ploner A, Fischer K, Horikoshi M, Sarin A-P, Thorleifsson G, Ladenvall C, Kals M, Kuningas M, Draisma HHM, Ried JS, van Zuydam NR, Huikari V, Mangino M, Sonestedt E, Benyamin B, Nelson CP, Rivera NV, Kristiansson K, Shen H-Y, Havulinna AS, Dehghan A, Donnelly LA, Kaakinen M, Nuotio M-L, Robertson N, de Bruijn RFAG, Ikram MA, Amin N, Balmforth AJ, Braund PS, Doney ASF, Döring A, Elliott P, Esko T, Franco OH, Gretarsdottir S, Hartikainen A-L, Heikkilä K, Herzig K-H, Holm H, Hottenga JJ, Hyppönen E, Illig T, Isaacs A, Isomaa B, Karssen LC, Kettunen J, Koenig W, Kuulasmaa K, Laatikainen T, Laitinen J, Lindgren C, Lyssenko V, Läärä E, Rayner NW, Männistö S, Pouta A, Rathmann W, Rivadeneira F, Ruokonen A, Savolainen MJ, Sijbrands EJG, Small KS, Smit JH, Steinthorsdottir V, Syvänen A-C, Taanila A, Tobin MD, Uitterlinden AG, Willems SM, Willemsen G, Witteman J, Perola M, Evans A, Ferrières J, Virtamo J, Kee F, Tregouet D-A, Arveiler D, Amouyel P, Ferrario MM, Brambilla P, Hall AS, Heath AC, Madden PAF, Martin NG, Montgomery GW, Whitfield JB, Jula A, Knekt P, Oostra B, van Duijn CM, Penninx BWJH, Davey Smith G, Kaprio J, Samani NJ, Gieger C, Peters A, Wichmann H-E, Boomsma DI, de Geus EJC, Tuomi T, Power C, Hammond CJ, Spector TD, Lind L, Orho-Melander M, Palmer CNA, Morris AD, Groop L, Järvelin M-R, Salomaa V, Vartiainen E, Hofman A, Ripatti S, Metspalu A, Thorsteinsdottir U, Stefansson K, Pedersen NL, McCarthy MI, Ingelsson E, Prokopenko I; for the European Network for Genetic and Genomic Epidemiology (ENGAGE) consortium. The role of adiposity in cardiometabolic traits: a Mendelian randomization analysis. PLoS Med 2013;10:e1001474.
    1. Boden-Albala B, Sacco RL.. Lifestyle factors and stroke risk: exercise, alcohol, diet, obesity, smoking, drug use, and stress. Curr Atheroscler Rep 2000;2:160–166.
    1. Larsson SC, Bäck M, Rees JM, Mason AM, Burgess S.. Body mass index and body composition in relation to 14 cardiovascular conditions in UK Biobank: a Mendelian randomization study. Eur Heart J 2020;41:221–226.
    1. van Vliet-Ostaptchouk JV, Snieder H, Lagou V.. Gene-lifestyle interactions in obesity. Curr Nutr Rep 2012;1:184–196.
    1. Jääskeläinen T, Paananen J, Lindström J, Eriksson JG, Tuomilehto J, Uusitupa M; Finnish Diabetes Prevention Study Group; Genetic predisposition to obesity and lifestyle factors–the combined analyses of twenty-six known BMI- and fourteen known waist:hip ratio (WHR)-associated variants in the Finnish Diabetes Prevention Study. Br J Nutr 2013;110:1856–1865.
    1. Day FR, Loos RJ.. Developments in obesity genetics in the era of genome-wide association studies. J Nutrigenet Nutrigenomics 2011;4:222–238.
    1. Eckel RH, Krauss RM.. American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee. Circulation 1998;97:2099–2100.
    1. Ghanta RK, LaPar DJ, Zhang Q, Devarkonda V, Isbell JM, Yarboro LT, Kern JA, Kron IL, Speir AM, Fonner CE, Ailawadi G.. Obesity increases risk-adjusted morbidity, mortality, and cost following cardiac surgery. J Am Heart Assoc 2017;6:e003831.
    1. Zhou X, Yu J, Li L, Gloy VL, Nordmann A, Tiboni M, Li Y, Sun X.. Effects of bariatric surgery on mortality, cardiovascular events, and cancer outcomes in obese patients: systematic review and meta-analysis. Obes Surg 2016;26:2590–2601.
    1. Carter AR, Gill D, Davies NM, Taylor AE, Tillmann T, Vaucher J, Wootton RE, Munafò MR, Hemani G, Malik R, Seshadri S, Woo D, Burgess S, Davey Smith G, Holmes MV, Tzoulaki I, Howe LD, Dehghan A.. Understanding the consequences of education inequality on cardiovascular disease: Mendelian randomisation study. BMJ 2019;365:l1855.
    1. Ge L, Sadeghirad B, Ball GDC, da Costa BR, Hitchcock CL, Svendrovski A, Kiflen R, Quadri K, Kwon HY, Karamouzian M, Adams-Webber T, Ahmed W, Damanhoury S, Zeraatkar D, Nikolakopoulou A, Tsuyuki RT, Tian J, Yang K, Guyatt GH, Johnston BC.. Comparison of dietary macronutrient patterns of 14 popular named dietary programmes for weight and cardiovascular risk factor reduction in adults: systematic review and network meta-analysis of randomised trials. BMJ 2020;369:m696.
    1. Ho FK, Gray SR, Welsh P, Petermann-Rocha F, Foster H, Waddell H, Anderson J, Lyall D, Sattar N, Gill JMR, Mathers JC, Pell JP, Celis-Morales C.. Associations of fat and carbohydrate intake with cardiovascular disease and mortality: prospective cohort study of UK Biobank participants. BMJ 2020;368:m688.
    1. Drouin-Chartier J-P, Chen S, Li Y, Schwab AL, Stampfer MJ, Sacks FM, Rosner B, Willett WC, Hu FB, Bhupathiraju SN.. Egg consumption and risk of cardiovascular disease: three large prospective US cohort studies, systematic review, and updated meta-analysis. BMJ 2020;368:m513.
    1. Li Z-H, Zhong W-F, Liu S, Kraus VB, Zhang Y-J, Gao X, Lv Y-B, Shen D, Zhang X-R, Zhang P-D, Huang Q-M, Chen Q, Wu X-B, Shi X-M, Wang D, Mao C.. Associations of habitual fish oil supplementation with cardiovascular outcomes and all cause mortality: evidence from a large population based cohort study. BMJ 2020;368:m456.
    1. Mozaffarian D, Hao T, Rimm EB, Willett WC, Hu FB.. Changes in diet and lifestyle and long-term weight gain in women and men. N Engl J Med 2011;364:2392–2404.
    1. Sun Y, Liu B, Snetselaar LG, Robinson JG, Wallace RB, Peterson LL, Bao W.. Association of fried food consumption with all cause, cardiovascular, and cancer mortality: prospective cohort study. BMJ 2019;364:k5420.
    1. Li Y, Schoufour J, Wang DD, Dhana K, Pan A, Liu X, Song M, Liu G, Shin HJ, Sun Q, Al-Shaar L, Wang M, Rimm EB, Hertzmark E, Stampfer MJ, Willett WC, Franco OH, Hu FB.. Healthy lifestyle and life expectancy free of cancer, cardiovascular disease, and type 2 diabetes: prospective cohort study. BMJ 2020;368:l6669.
    1. Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, Franklin B, Kris-Etherton P, Harris WS, Howard B, Karanja N, Lefevre M, Rudel L, Sacks F, Van Horn L, Winston M, Wylie-Rosett J.. Summary of American Heart Association diet and lifestyle recommendations revision 2006. Arterioscler Thromb Vasc Biol 2006;26:2186–2191.
    1. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney M-T, Corrà U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Løchen M-L, Löllgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Binno S; ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37:2315–2381.
    1. Sirugo G, Williams SM, Tishkoff SA.. The missing diversity in human genetic studies. Cell 2019;177:26–31.
    1. Kyrgiou M, Kalliala I, Markozannes G, Gunter MJ, Paraskevaidis E, Gabra H, Martin-Hirsch P, Tsilidis KK.. Adiposity and cancer at major anatomical sites: umbrella review of the literature. BMJ 2017;356:j477.
    1. Kalliala I, Markozannes G, Gunter MJ, Paraskevaidis E, Gabra H, Mitra A, Terzidou V, Bennett P, Martin-Hirsch P, Tsilidis KK.. Obesity and gynaecological and obstetric conditions: umbrella review of the literature. BMJ 2017;359:j4511.
    1. Mascha EJ.Alpha, beta, meta: guidelines for assessing power and type I error in meta-analyses. Anesth Analg 2015;121:1430–1433.
    1. Thomas J, Askie LM, Berlin JA, Elliott JH, Ghersi D, Simmonds M, Takwoingi Y, Tierney JF, Higgins JP.. Prospective approaches to accumulating evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., eds. Cochrane Handbook for Systematic Reviews of Interventions. London: Cochrane; 2019. p547–568.
    1. Riley RD, Jackson D, Salanti G, Burke DL, Price M, Kirkham J, White IR.. Multivariate and network meta-analysis of multiple outcomes and multiple treatments: rationale, concepts, and examples. BMJ 2017;358:j3932.
    1. Riley RD, Moons KG, Snell KI, Ensor J, Hooft L, Altman DG, Hayden J, Collins GS, Debray TP.. A guide to systematic review and meta-analysis of prognostic factor studies. BMJ 2019;364:k4597.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe